Alzheimer's disease (AD) is historically difficult to treat, in part due the inaccessible nature of brain pathology. Amyloid-β (Aβ) and tau proteins drive pathology by forming toxic oligomers that eventually… Click to show full abstract
Alzheimer's disease (AD) is historically difficult to treat, in part due the inaccessible nature of brain pathology. Amyloid-β (Aβ) and tau proteins drive pathology by forming toxic oligomers that eventually deposit as insoluble amyloid plaques and neurofibrillary tangles. Recent clinical studies suggest that effective drugs must specifically target oligomers, not native monomers or insoluble fibrils. Passive immunotherapy is one promising pharmaceutical strategy used to specifically target these oligomers in situ. Using the specificity of antibodies coupled with the natural power of the body's immune response, this treatment provides an opportunity for safe clearance of pathogenic protein species from the brain. Passive immunotherapies against Aβ and tau oligomers have progressed to clinical trials, with many currently in progress. Biochemical studies of antibody-oligomer complexes have helped identify previously unknown toxic epitopes, thus providing knowledge to the AD field as a whole. This mini-review focuses on the efforts to develop passive immunotherapy treatments for AD and discusses the knowledge gained from recent failures and clinical trials in progress.
               
Click one of the above tabs to view related content.